Compare TENB & ZYME Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TENB | ZYME |
|---|---|---|
| Founded | 2002 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.3B | 1.9B |
| IPO Year | 2018 | 2022 |
| Metric | TENB | ZYME |
|---|---|---|
| Price | $17.92 | $26.81 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 18 | 11 |
| Target Price | $32.76 | ★ $38.90 |
| AVG Volume (30 Days) | ★ 2.4M | 560.0K |
| Earning Date | 04-28-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 3.23 | ★ 33.33 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $999,405,000.00 | $105,965,000.00 |
| Revenue This Year | $9.37 | $162.82 |
| Revenue Next Year | $7.04 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 11.04 | ★ 38.87 |
| 52 Week Low | $15.85 | $9.03 |
| 52 Week High | $35.69 | $28.49 |
| Indicator | TENB | ZYME |
|---|---|---|
| Relative Strength Index (RSI) | 41.27 | 66.40 |
| Support Level | $17.28 | $22.28 |
| Resistance Level | $21.25 | $27.35 |
| Average True Range (ATR) | 1.00 | 0.93 |
| MACD | 0.01 | 0.25 |
| Stochastic Oscillator | 42.12 | 97.68 |
Founded in 2002, Tenable is a cybersecurity company that began providing vulnerability management solutions under its Nessus software. In recent years, Tenable has expanded its portfolio to provide a broader range of exposure management modules. Solutions include cloud security and compliance, active directory management, operational technology security and advanced vulnerability analytics. The Maryland-based company went public in 2018.
Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated therapeutic product candidates. Its clinical candidate, zanidatamab, is a novel HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. It is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.